# US 2014/0271686 A1 · Anti-(+) -methamphetamine monoclonal antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271686 A1
- Document ID: US20140271686A1
- Status: Published application
- Kind: A1
- Application number: 13/802,688
- Filed: 2013-03-13
- Published: 2014-09-18
- Earliest claimed: 2013-03-13
- Assignees: Board of Trustees of the University of Arkansas
- Applicants: Board of Trustees University of Arkansas
- Inventors: Samuel Michael Owens; Ralph Henry; Alicia Brown
- Web page: https://patentgrep.com/patent/US20140271686A1

## CPC

- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61P 25/30: for treating abuse or dependence
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.

## Claims

### Claim 1

An isolated antibody, wherein the antibody specifically binds (+) methamphetamine and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:10 with zero to two amino acid substitutions.

### Claim 2 (depends on 1)

The isolated antibody of claim 1, wherein the antibody further comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

### Claim 3 (depends on 2)

The isolated antibody of claim 2, wherein the antibody is encoded by a nucleic acid sequence comprising a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

### Claim 4 (depends on 1)

The isolated antibody of claim 1, further comprising SEQ ID NO: 8 and SEQ ID NO:9, each with zero to two amino acid substitutions.

### Claim 5 (depends on 1)

The isolated antibody of claim 1, wherein the antibody is selected from the group consisting of a single-chain antibody, an antibody fragment, a bispecific antibody, a chimeric antibody, or a humanized antibody.

### Claim 6 (depends on 1)

The isolated antibody of claim 1, wherein the antibody further binds an epitope within a metabolite of (+) methamphetamine or a (+) methamphetamine-like analog.

### Claim 7 (depends on 1)

The isolated antibody of claim 1, wherein the antibody further comprises SEQ ID NO:7.

### Claim 8 (depends on 1)

The isolated antibody of claim 1, wherein the antibody further comprises at least three amino acid sequences selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

### Claim 9

An isolated antibody capable of specifically binding (+) methamphetamine and comprising a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 7 with zero to two amino acid substitutions.

### Claim 10 (depends on 9)

The isolated antibody of claim 9, further comprising the amino acid sequence of SEQ ID NO: 5 with zero to two amino acid substitutions and the amino acid sequence of SEQ ID NO: 6 with zero to two amino acid substitutions.

### Claim 11 (depends on 10)

The isolated antibody of claim 10, further comprising the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, wherein each amino acid sequence has between zero and two amino acid substitutions.

### Claim 12 (depends on 9)

The isolated antibody of claim 9, wherein the antibody is selected from the group consisting of a single-chain antibody, an antibody fragment, a bispecific antibody, a chimeric antibody, or a humanized antibody.

### Claim 13 (depends on 9)

The isolated antibody of claim 9, wherein the anti-(+) methamphetamine antibody binds an epitope within a metabolite of (+) methamphetamine or a (+) methamphetamine-like analog.

### Claim 14 (depends on 1)

A method for treating at least one medical problem associated with methamphetamine use in a subject which comprises administering an effective amount of the antibody of claim 1 to the subject to treat at least one medical problem.

### Claim 15 (depends on 14)

The method of claim 14, wherein the treating includes preventing, attenuating, reversing, or improving at least one symptom or sign of methamphetamine use in a subject.

### Claim 16 (depends on 14)

The method of claim 14, wherein the medical problem associated with methamphetamine use is selected from the group consisting of methamphetamine addiction and methamphetamine abuse.

### Claim 17 (depends on 14)

The method of claim 14, wherein the medical problem associated with methamphetamine use is selected from the group consisting of acute methamphetamine overdose, chronic methamphetamine overdose, and methamphetamine-use relapse.

### Claim 18 (depends on 14)

The method of claim 14, wherein the anti-(+) methamphetamine antibody binds an epitope within (+) methamphetamine, a metabolite of (+) methamphetamine, or (+) methamphetamine-like analog.

### Claim 19 (depends on 14)

The method of claim 14, wherein administering the antibody slows the rate of (+) methamphetamine entry into the brain of a subject.

### Claim 20 (depends on 14)

The method of claim 14, wherein the administration of the antibody reduces the frequency of methamphetamine use relapse in a subject addicted to methamphetamine.
